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httpcense.Abstract Risk of death is high in patients with pulmonary embolism (PE) because of right ventric-
ular (RV) failure. Plasma levels of brain natriuretic peptide (BNP) are increased in cases of isolated
chronic right ventricular dysfunction (RVD) and chronic pulmonary hypertension. However, little
is known about BNP secretion during acute RVD caused by acute PE.
The aim of this study is to determine BNP levels in patients with acute PE with and without RVD
and to assess its role in prediction of severity and outcome of these patients.
Patients and methods: This study was conducted on 47 patients with conﬁrmed acute PE who
were admitted to the intensive care unit (ICU) of Chest Department, Zagazig University Hospitals.
Patients enrolled in this study were subjected to: (a) Transthoracic echocardiography, (b) Measure-
ment of BNP plasma levels, (c) Measurement of D-dimer serum levels and d) Computed tomogra-
phy pulmonary angiography (CTPA).
Results: There was statistically highly signiﬁcant increase in plasma level of BNP (pg/mL) in
patients with RVD than those without it. There were highly signiﬁcant positive correlations between
plasma level of BNP (pg/mL) and both RV diameter (mm) and RVSP (mmHg). A plasma BNP
level >72.5 pg/mL can predict occurrence of RVD, while a plasma level of BNP >150 pg/mL
can predict death in patients with acute PE.
Conclusion: An elevated plasma level of BNP is a prognostic factor for short-term mortality and
overall short-term complicated clinical outcome, and it is a powerful indicator of RVD in patients
with acute PE in the absence of left ventricular dysfunction (LVD).
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Risk of death is high in patients with PE because of RV failure.
Mortality rate increases with worsening RVD. The determina-
tion of RVD is particularly important because outcome may
improve with substantial afterload reduction by treatment with
thrombolytic therapy [1].is. Production and hosting by Elsevier B.V.
9.002
426 R. Naﬁe et al.Although normotensive patients with RV overload have
a moderately increased in-hospital mortality rate, up to
5–13%, there is an ongoing debate as to whether this group
should be treated by anticoagulation or by more aggressive
methods [2].
Plasma concentrations of BNP are increased in patients
with chronic heart failure and accurately predict left ventricu-
lar ejection fraction (LVEF), exercise capacity, morbidity and
mortality in these patients [3].
BNP levels are also increased in cases of isolated chronic
RVD and chronic pulmonary hypertension [4]. However, little
is known about BNP secretion during acute RVD caused by
acute PE.
The aim of this study is to determine BNP levels in patients
with acute PE with and without RVD and to assess its role in
prediction of severity and outcome of these patients.
Patients and methods
This study was conducted on 47 patients with conﬁrmed acute
PE who were admitted to the intensive care unit (ICU) of
Chest Department, Zagazig University Hospitals between
May 2010 and October 2011. They were 26 males and 21 fe-
males with a mean age of 47.3 ± 10.3.
Inclusion criteria
Patients with acute PE were diagnosed as following [5]:
1- Thorough medical history taking stressing upon history
of recent major surgery, prior deep venous thrombosis
(DVT), cancer or pills therapy.
2- Typical clinical presentation: acute onset of dyspnea,
tachypnea, chest pain, syncope, hypotension, and/or
shock.
3- Laboratory: positive results of the serum D-dimer
enzyme-linked immunosorbent assay (>500 ng/mL).
4- CTPA.
5- Echocardiography: abnormal echocardiography results.
6- The diagnosis was further supported by lower-limbs
venous ultrasound scanning examination, blood gas
analysis or abnormal electrocardiogram results (tachy-
cardia, SI QIII TIII type, complete or incomplete right
bundle-branch block, inverted T waves in right precor-
dial leads).Exclusion criteria [6,7]
Patients with any of the following comorbidities which might
affect natriuretic peptides levels and accuracy were excluded:
1- Chronic pulmonary diseases.
2- Chronic cardiovascular diseases.
3- Acute and chronic renal failure.
4- Endocrinal disorders as hyperaldosteronism, cushing ‘s
syndrome.
5- Advanced liver cirrhosis with ascites.
6- Anemia.
7- Sepsis.
8- Previous documented PE, prior heart failure or morbid
obesity.
9- Severe neurological diseases as subarachnoid hemor-
rhage, stroke or trauma.Patients enrolled in this study were subjected to
Transthoracic echocardiography [8]:. Echocardiography was
performed for all patients within the ﬁrst day of admission
and independent analysis was performed by a reader blinded
to the clinical outcome and BNP levels of the patients.
Diagnosis of RVD was made in the presence of any of these
criteria:
1- Dilation of RV (diastolic diameter > 32 mm) or a RV/
LV end- diastolic diameter ratio > 1 in the 4 chamber
view.
2- Hypokinesis of RV.
3- Abnormal motion of interventricular septum.
4- Right ventricular systolic pressure (RVSP) >30 mmHg,
normally RVSP = 20–30 mmHg.
Measurement of BNP plasma levels. In the studied patients,
blood was sampled on admission (after 6–12 h of symptoms
beginning) and before initiation of therapy. B-type natriuretic
peptide was measured using the Triage B-Type Natriuretic
Peptide Test (Biosite Inc., San Diego, CA). The Triage BNP
Test is a ﬂuorescence immunoassay for the quantitative deter-
mination of BNP in whole blood and plasma [9].
The peripheral venous blood was collected (3 ml) into a
sampling tube containing EDTA as the anticoagulant. Within
15 min, BNP concentrations were determined [3].
Measurement of serum D-dimer levels [10]. The levels of
D-dimer were determined by an automated quantitative sys-
tem, VIDAS D-Dimer Exclusion instrument manufactured
by bioMerieux S.A. France. The assay principle combines
two step enzyme immunoassay sandwich method with a ﬁnal
ﬂuorescent detection, a technique called enzyme linked ﬂuores-
cent assay (ELFA). Sample was collected (2 ml peripheral ve-
nous blood) in vacutainer tubes containing trisodium citrate
0.109 mol/L, (3.2%), Centrifugation at 3000 rpm for 15 min.
Measurement was done following manufacturer instructions
(Normal value below 500 ng/mL). The detection limits ranges
from, 45 ng/mL to the upper limit of 10,000 ng/mL, samples
concentration more the 10,000 ng/mL must be diluted 1/5 by
special diluents in the kit and retested.Statistical analysis
Statistical analysis was performed with the SPSS statistical
software package (SPSS Inc., Chicago, IL).
Data presented by mean ± SD for quantitative continuous
data was calculated by one way analysis for variance (F test).
Qualitative data was presented by number and percentage
and association was tested by Chi – square test.
P-value <0.05 is considered signiﬁcant.
Correlation coefﬁcient (r) were calculated for testing associ-
ation between quantitative variables. P-value <0.05 is consid-
ered signiﬁcant.
Receiver Operating Characteristic (ROC) curve was used
for predicting cut-off levels of plasma BNP at which RVD
and death occurred and area under the curve (AUC), 95%
conﬁdence interval (CI) were presented, sensitivity, speciﬁcity,
positive predictive value (PPV), negative predictive value
(NPV) and Kappa measurement were calculated. P-value
<0.05 is considered signiﬁcant.
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Table 1 showed general characteristics of the studied pa-
tients. There were statistically non-signiﬁcant differences be-
tween patients with and without RVD as regards age, sex,
systolic blood pressure or the presence of risk factors. But,
there was statistically signiﬁcant increase in the presence of
syncope in patients with RVD than those without RVD
(P= 0.023).
Table 2 showed statistically highly signiﬁcant increase
(P= 0.0001) in plasma level of BNP (pg/mL) in patients with
RVD than those without it, while statistically non-signiﬁcant
increase (P= 0.303) in serum level of D-dimer (ng/mL) was
observed in patients with RVD than those without it. As re-
gards PaO2, there was statistically highly signiﬁcant decrease
(P= 0.002) in PaO2 in patients with RVD than those without
it. On the other hand, there was statistically non-signiﬁcant in-
crease (P= 0.08) in PaCO2 in patients with RVD than those
without it.
Table 3 showed statistically highly signiﬁcant increase
(P= 0.0001) in RV diameter (mm) and RVSP (mmHg) in pa-
tients with RVD than those without it, but there was statisti-
cally non-signiﬁcant difference (P= 0.07) regarding LVEDD
(mm). As regards RV hypokinesis, all patients with RVD
had RV hypokinesis, also only 11 (47.83%) patients with
RVD had abnormal motion of interventricular septum oppo-
site non of those without RVD having these abnormalities.
Table 4 showed statistically highly signiﬁcant positive cor-
relations (P= 0.0001) between plasma level of BNP (pg/mL)
and both RV diameter (mm) and RVSP (mmHg) in patients
with RVD. While the correlation between plasma level of
BNP (pg/mL) and LVEDD (mm) was statistically non-signiﬁ-
cant (P= 0.538) in patients with RVD.Table 2 Laboratory ﬁndings of the studied patients with and witho
Parameter With RVD (n= 23)
Plasma BNP (pg/mL) 170 ± 85.84
Serum D-dimer (ng/mL) 2179.38 ± 929.6
PaO2 (mmHg) 66.48 ± 12.66
PaCO2 (mmHg) 39.87 ± 15.69
Table 1 General characteristics of the studied patients with and wi
Characteristic With RVD (n= 23)
Age (years) 46.96 ± 7.8
Sex, no (%):
Male 14 (53.8%)
Female 9 (42.9%)
Symptoms, no (%):
Dyspnea 18 (51.4%)
Chest pain 13 (48.1%)
Syncope 7 (87.5%)
Systolic blood pressure (M± SD) 112.39 ± 10.36
Risk factors, no (%):
Recent major surgery 7 (70%)
Prior DVT 6 (60%)
Cancer 1 (16.7%)
Pills therapy 1 (25%)Table 5 showed statistically highly signiﬁcant negative cor-
relations between plasma level of BNP (pg/mL) and PaO2 both
in all studied patients and in patients with RVD (P= 0.0001)
and (P= 0.003) respectively.
Figs. 1 and 2 showed a receiver operating characteristic
(ROC) analysis in which sensitivity was calculated with those
patients who had RVD and who died during the study. The
area under the ROC curve (AUC), PPV, NPV, sensitivity
and speciﬁcity for cut-off levels of plasma BNP (pg/mL) were
calculated in Tables 6 and 7. A plasma BNP level >72.5 pg/
mL had high sensitivity (95.7%) in predicting RVD in patients
with acute PE with normal left ventricular (LV) systolic func-
tion. Also, at this cut-off level, the PPV and NPV for detection
of RVD were 73.3% and 94.1% respectively with low speciﬁc-
ity which was 66.7% (P= 0.0001). A plasma level of BNP
>150 pg/mL had sensitivity of 80%, speciﬁcity of 78.6%,
PPV of 30.8% and high NPV of 97.1% in predicting mortality
in patients with acute PE (P= 0.006).
Table 8 showed the outcome of the studied patients during
hospitalization and there was statistically signiﬁcant increase
(P= 0.041) in the duration of hospital stay in patients with
RVD than those without it. Shock, resuscitation, the need
for MV and in-hospital death occurred only in patients with
RVD.
Discussion
The diagnosis of RVD in acute PE is of upmost importance,
because RVD is associated with mortality and there is evidence
that clinical outcome can be improved by rapid dissolution of
the thrombi with thrombolytic therapy [11]. Echocardiography
is a readily available and generally accepted sensitive bedside
method for detection of RVD [8]. However, the possibility ofut RVD.
Without RVD (n= 24) P-value
67.13 ± 9.58 0.0001
1936.09 ± 638.32 0.303
77.92 ± 10.81 0.002
33.46 ± 7.63 0.08
thout RVD.
Without RVD (n= 24) P-value
47.75 ± 10.08 0.765
12 (46.2%) 0.454
12 (57.1%)
17 (48.6%) 0.55
14 (51.9%) 0.9
1 (12.5%) 0.023
114.17 ± 8.81 0.627
3 (30%) 0.168
4 (40%) 0.43
5 (83.3%) 0.188
3 (75%) 0.6
Table 3 Comparison between the studied patients with and without RVD as regards echocardiographic ﬁndings.
Parameter With RVD (n= 23) Without RVD (n= 24) P-value
LVEDD (mm) 40.83 ± 6.32 37.29 ± 7.1 0.07
RV diameter (mm) 39.09 ± 9.12 25.17 ± 3.38 0.0001
RV hypokinesis, no (%) 23 (100%) 0.0 –
Abnormal motion of interventricular septum, no (%) 11 (47.83%) 0.0 –
RVSP (mmHg) 34.52 ± 9.44 24.71 ± 2.33 0.0001
Table 4 Correlation between plasma level of BNP (pg/mL)
and echocardiographic ﬁndings in patients with RVD.
Plasma BNP
(pg/mL)
LVEDD
(mm)
RV diameter
(mm)
RVSP
(mmHg)
r-value 0.092 0.796 0.611
P-value 0.538 0.0001 0.0001
Table 5 Correlation between plasma level of BNP (pg/mL)
and both partial arterial oxygen tension (PaO2) and partial
arterial carbon dioxide tension (PaCO2) in all studied patients
and in those with RVD.
Plasma BNP (pg/mL) All studied patients Patients with RVD
PaO2 (mmHg) 0.611** 0.583**
PaCO2 (mmHg) 0.277 0.147
** P< 0.01.
Figure 1 ROC curve for prediction of RVD in acute PE.
Figure 2 ROC curve for prediction of death in acute PE.
Table 6 Prediction of both RVD and mortality for all studied
patients: area under the receiver operating characteristic (ROC)
curve plot analysis.
Cut-oﬀ level AUC 95% CI
RVD >72.5 0.923 0.846–1.000
Death >150 0.90 0.81–0.99
Table 7 Sensitivity, speciﬁcity, PPV and NPV at cut-off levels
of both RVD and mortality of plasma BNP (pg/mL).
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Kappa P-value
RVD 95.7 66.7 73.3 94.1 0.62 0.0001
Death 80 78.6 30.8 97.1 0.34 0.006
428 R. Naﬁe et al.implementing a rapid and effective triage with biohumoral
markers such as BNP may be of value [12]. The availabilityof biomarkers like BNP or NT-proBNP able to identify
RVD patients early and to contribute to risk stratiﬁcation is
potentially important, especially when echocadiography
assessment is not available [13].
Table 8 Outcome of the studied patients with and without RVD.
Parameter With RVD (n= 23) Without RVD (n= 24) P-value
Shock, no (%) 6 (100%) 0.0 –
Resuscitation, no (%) 4 (100%) 0.0 –
Need for M.V., no (%) 7 (100%) 0.0 –
Duration of hospital stay (M± SD) 20.25 ± 2.36 18.17 ± 4.18 0.041
In-hospital death, no (%) 5 (100%) 0.0 –
M.V.: mechanical ventilation.
Can brain natriuretic peptide predict the outcome in patients with acute pulmonary embolism? 429In contrast with echocardiography, biochemical markers
can be promptly obtained in all patients with acute PE and
could be more suitable in this setting. A biomarker-based strat-
iﬁcation is relevant mainly in hemodynamically stable patients
whose adverse outcome cannot be easily predicted by clinical
examination [14]. So, the aim of this work is to determine plas-
ma level of BNP in patients with acute PE with and without
RVD and to assess its role in prediction of severity and out-
come of these patients.
BNP is produced to a larger degree from ventricular myo-
cytes. The principal stimulus for BNP synthesis and secretion
is cardiomyocyte stretch [15].
Elevated plasma levels of BNP have been found in patients
with congestive heart failure and even in those with asymptom-
atic LV systolic dysfunction. Moreover, elevated plasma BNP
was found in patients with primary pulmonary hypertension
and chronic thromboembolic pulmonary hypertension [16].
Interestingly, elevated plasma BNP was reported to help differ-
entiate pulmonary from cardiac aetiologies of acute dyspnea
[17].
In our study, there was statistically highly signiﬁcant in-
crease in plasma level of BNP (pg/mL) in patients with RVD
than those without it, while statistically non-signiﬁcant in-
crease in serum D-dimer level (ng/mL) in patients with RVD
than those without it was observed (Table 2). Regarding echo-
cardiographic ﬁndings in our study, there was statistically
highly signiﬁcant increase in RV diameter (mm) and RVSP
(mmHg) in patients with RVD than in those without it. But,
there was statistically non-signiﬁcant difference between pa-
tients with and without RVD as regards LVEDD (mm). RV
hypokinesis was observed only in patients with RVD and 11
(47.83%) patients with RVD had abnormal motion of inter-
ventricular septum (Table 3). Also, in our study, there were
highly signiﬁcant positive correlations between plasma level
of BNP (pg/mL) and both RV diameter (mm) and RVSP
(mmHg) (Table 4).
Plasma BNP elevation in acute PE is probably caused by in-
creased myocardial shear stress, mainly in the right ventricle,
and depends on the degree and dynamics of embolic events
[18].
Prohormone in normal ventricular myocytes is not stored
to a signiﬁcant amount. Thus, it takes several hours for the
plasma natriuretic peptides levels to increase after the onset
of acute cardiomyocyte stretch. This includes myocardial
BNP messenger ribonucleic acid (mRNA) synthesis, prohor-
mone synthesis and plasma release [19].
In consistence with our results, Pruszczyk et al. [20] re-
ported that plasma NT-proBNP was increased in almost all
cases of clinically massive and submassive acute PE, whichare accompanied by RV overload and dyspnea, while in pa-
tients without echocardiographic signs of RVD, NT-proBNP
elevation was found in only 50% of patients.
Also, Kruger et al. [8] noticed elevated BNP levels in 64%
of their patients with RVD, but in only 6% of the patients
without dysfunction.
Supporting our results, Kruger et al. [21] found highly dy-
namic BNP release kinetics with rapidly falling BNP levels
after initiation of therapy, especially after thrombolysis.
Regarding echocardiography results, a sudden increase in
pressure load on the RV is poorly tolerated due to the inability
of its thin wall to develop and sustain high wall tension and
stress. The increase in right ventricular pressures may result
in shifting of the interventricular septum toward LV, reducing
the left ventricular volume [22]. Myocardial wall stress is a po-
tent stimulus for the increased synthesis and secretion of BNP,
which gives the biological plausibility for elevation of BNP and
NT-proBNP in the setting of acute PE and RV strain [23].
In agreement with our results, Klok et al. [24] demonstrated
very strong correlation between increased levels of BNP and
RVD on echocardiography in patients with acute PE. Also,
Tulevski et al. [25] reported that in isolated chronic RV over-
load, BNP levels are elevated and correlate positively with
mean pulmonary artery pressure and RV end-diastolic pres-
sure and negatively with cardiac output and RV ejection
fraction.
Regarding D-dimer results, D-dimer levels could be re-
lated to the extent of thrombotic load [26]. The association
between D-dimer levels and the presence of RVD at CT angi-
ography was evaluated in previous studies. Ghanima et al.
[27] and Gutte et al. [28] reported that a positive correlation
was found between RVD at CT angiography and D-dimer
levels, while in Jeebun et al. [29] and Turedi et al. [30] studies,
this correlation was not conﬁrmed. A positive association was
found in one study between D-dimer levels and RVD at
echocardiography [31].
D-dimer appears to be a relatively poor predictor of prog-
nosis in PE in multi-variable analysis [32].
Biochemical markers of myocardial stretch (e.g. BNP) may
be more sensitive in the detection of RV overload than echo-
cardiography [20]and biomarker determination in stable acute
PE patients appears to be a valuable diagnostic adjunct, and
in some cases may even substitute echocardiography in in-
hospital and long-term risk stratiﬁcation [33]. This is because;
echocardiography suffers from several limitations as; it is a
user-dependent method, not fully reproducible and it is not
always immediately available [34]. Also, a number of echocar-
diographic parameters have been proposed to analyze RVD.
Some of them are difﬁcult to obtain and/or are missing [14].
430 R. Naﬁe et al.In some studies, RV echocardiographic analysis was insufﬁ-
cient in more than 10% of patients which could explain
discrepancies regarding RVD – related prognosis among
studies.
Regarding hypoxemia in this study, there was statistically
highly signiﬁcant decrease in PaO2 in patients with RVD than
those without it (Table 2). Also, there were statistically highly
signiﬁcant negative correlations between plasma level of BNP
(pg/mL) and PaO2 both in all studied patients and in patients
with RVD (Table 5).
In consistence with our results, Goldhaber and Elliott [5] re-
ported that a low pressure of oxygen in venous blood may con-
tribute to arterial hypoxemia when PE causes RV failure. Also,
Pruszczyk et al. [20] found that increased plasma NT-proBNP
and decreased oxygen saturation inﬂuenced in-hospital deaths
and serious adverse events.
To evaluate the potential to predict the occurrence of RVD
and also death from acute PE in clinically stable patients, a re-
ceiver operating characteristic (ROC) analysis was performed
(Figs. 1 and 2). A plasma BNP level >72.5 pg/mL had high
sensitivity (95.7%) in predicting RVD in patients with acute
PE with normal LV systolic function. Also, at this cut-off level,
the PPV and NPV for detection of RVD were 73.3% and
94.1% respectively with low speciﬁcity which was 66.7% (Ta-
ble 7). But, a plasma level of BNP >150 pg/mL had sensitivity
of 80%, speciﬁcity of 78.6%, PPV of 30.8% and high NPV of
97.1% in predicting mortality in hemodynamically stable pa-
tients with acute PE (Table 7).
Our results are in consistence with Kruger et al. [8] who re-
ported that a BNP level of 75 pg/mL was a cut-off value in
their study for ruling out RVD, which is close to our result.
Mikulewicz and Lewczuk [33] demonstrated that the cut-off
value to diagnose 95% of patients with mild disease course was
<50 pg/mL. But, Pieralli et al. [35] reported a BNP level of
<85 pg/mL was shown to exclude echocardiographic ﬁndings
of RV overload in normotensive patients with acute PE with a
high degree of accuracy and this result is consistent with our
result.
Regarding mortality prediction, Cavallazzi et al. [23] found
that patients with acute PE who showed in-hospital mortality
had an elevated BNP level utilizing a cut-off level of 100 pg/
mL and this level is in accordance with this study. In contrast,
Mikulewicz and lewczuk [33] reported that all patients with
acute PE with BNP over 527 pg/mL revealed RV overload fea-
tures in echocardiography; all acute complications and deaths
occurred in these patients.
Regarding the severity of acute PE and its outcome during
hospitalization of our studied patients, there was statistically
signiﬁcant increase in the number of patients who had syncope
[7(87.5%)] and in the duration of hospital stay in patients with
RVD than those patients without it (Tables 1 and 8). But, there
was statistically non-signiﬁcant difference in systolic blood
pressure between patients with and without RVD (Table 1).
Also, we found shock, resuscitation, the need for M.V. and
in-hospital death only among patients with RVD and with ele-
vated BNP (Table 8).
The hemodynamic response to PE depends on the size of
the embolus, coexistent cardiopulmonary disease and neuro-
humoral effects [5].
Normotensive patients with acute PE and no evidence of
RVD generally have a benign hospital course, while patientswith RVD on echocardiography have an increased risk of
hypotension, cardiogenic shock and early death [36].
No reliable clinical parameter could differentiate patients
with RVD from the others. This subgroup of patients with si-
lent RVD, so-called sub-massive PE, has a high risk of death
or hemodynamic instability during the ﬁrst days of admission
[37]. Logeart et al. [14] observed a high proportion of patients
with acute PE with echocardiographic evidence of RVD with
neither hypotension nor evidence of heart failure.
Previous studies or surveys reported that in-hospital prog-
nosis of patients with RVD was worse than that of patients
without RVD. Consequently, aggressive treatment such as
thrombolysis has been proposed in these patients [38].
Supporting our results, Pieralli et al. [35] and Tulevski et al.
[39] reported that 29% of their normotensive patients with
acute PE had increased BNP at presentation and this high level
of BNP predicted early complications. Also, Klok et al. [24]
meta-analysis demonstrated a signiﬁcant relation between high
levels of BNP and deterioration of clinical condition in pa-
tients with acute PE.
Also, Lippi and Targher [40] and Jimenez et al. [41] re-
ported that in hemodynamically stable patients with acute
PE, there is a signiﬁcant association between PE-speciﬁc mor-
tality and raised natriuretic peptides and the NT-proBNP lev-
els might provide faster and equally reliable prognostic
information as that provided by echocardiography alone.
In contrast, Kruger et al. [21] demonstrated that all pa-
tients with acute PE presenting with syncope necessitating
cardiopulmonary resuscitation showed normal BNP levels.
Thus, normal BNP levels don’t exclude severe PE. This
might be due to an insufﬁcient time span for RV BNP pro-
duction and secretion as a consequence of sudden RV pres-
sure overload resulting in syncope with cardiac arrest in
those patients and this is the most serious obstacle against
BNP use in PE patients.
Also, Coutance et al. [13] found that BNP levels may not
correlate well with cardiovascular outcomes in some patients
with PE of acute onset because of the obligatory delay in
BNP mRNA upregulation and subsequent protein release in
the serum. Indeed, it takes several hours for the BNP levels
to increase after the onset of acute myocardial stretch.
Markers of RVD (i.e. echocardiography, spiral CT or
BNP testing) and myocardial injury (i.e. cardiac troponin
T or I testing) identify high risk normotensive patients with
PE. So far, a single test has not had a sufﬁcient positive pre-
dictive value for PE - speciﬁc mortality to guide the initia-
tion of thrombolytic therapy. Future studies should assess
if the combination of complete lower limb compression
ultrasound (CCUS) testing with prognostic tools indicating
myocardial injury or RVD might offer an advantage com-
pared with each test alone with regard to the identiﬁcation
of normotensive patients with acute PE at high-risk of PE-
associated mortality [41].Conclusion
An elevated plasma level of BNP is a prognostic factor for
short-term mortality and overall short- term complicated clin-
ical outcome, and it is a powerful indicator of RVD in patients
with acute PE in the absence of LVD.
Can brain natriuretic peptide predict the outcome in patients with acute pulmonary embolism? 431While plasma BNP measurements may become part of the
risk stratiﬁcation in acute PE, its positive predictive value
alone remains low and its high negative predictive value is cer-
tainly more useful to identify patients with RVD (at cut-off le-
vel >72.5 pg/mL) and also to predict mortality of patients (at
cut-off level >150 pg/mL).
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